Advertisement
UK markets open in 2 hours 25 minutes

  • NIKKEI 225

    37,152.35
    -927.35 (-2.44%)
     

  • HANG SENG

    16,184.02
    -201.85 (-1.23%)
     

  • CRUDE OIL

    84.81
    +2.08 (+2.51%)
     

  • GOLD FUTURES

    2,401.70
    +3.70 (+0.15%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • Bitcoin GBP

    50,157.87
    +251.25 (+0.50%)
     

  • CMC Crypto 200

    1,286.71
    +401.17 (+44.07%)
     

  • NASDAQ Composite

    15,601.50
    -81.87 (-0.52%)
     

  • UK FTSE All Share

    4,290.02
    +17.00 (+0.40%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

Teva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?

Alex Carchidi, The Motley Fool
·4-min read
Teva Pharmaceuticals Just Made a Big Announcement, but Is It a Buy?

On May 18, Teva Pharmaceuticals (NYSE: TEVA) announced that it was planning to execute a strategic pivot that would return the company to growth after a long period of stagnation. Between the upcoming fruits of its biosimilar generic medicines pipeline and its anticipated investments in expanding its pipeline assets, management is hoping to mark a turnaround point within the next few years and meet its financial targets for 2027. Generally, generic drug manufacturers are companies that enjoy stable demand for cheaper copies of critical medicines.

Continue reading